The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials
Open accessAbstract
Background Efficacy analysis of the combined IBCSG TEXT and SOFT trials showed a significant disease-free survival benefit for exemestane plus ovarian function suppression (OFS) compared with tamoxifen +OFS. We present patient-reported outcomes from these trials. Methods Between 7 November 2003 and 7 April 2011, 4717 premenopausal patients with hormone-receptor positive breast cancer were enrolled in TEXT or SOFT to receive unblinded adjuvant treatment with 5 years of exemestane+OFS or tamoxifen+OFS. Chemotherapy use was optional. Randomization was performed via IBCSG’s internet-based system with the use of permuted blocks and was stratified by chemotherapy use and lymph nodes status. Patients completed a quality of life (QoL) form including several global and symptom-specific indicators at baseline, every 6 months for 24 months, then annually during years 3 to 6. Differences in change of QoL from baseline between the two treatments were tested at short-, mid-, and long-term using mixed-models for repeated measures, for each trial with and without chemotherapy and overall. The analysis was intention-to-treat using treatment as randomly assigned. At the time of analysis, the median follow-up was 5·7 years (IQR, 3·7 to 6·9 years), with treatment and follow-up of patients ongoing. Findings Patients reported considerable worsening from baseline in key endocrine symptoms. Those on tamoxifen+OFS were more affected by hot flushes and sweats over five years than those on exemestane+OFS, although these symptoms improved. Patients on exemestane+OFS reported more vaginal dryness, greater loss of sexual interest, and difficulties becoming aroused. These differences persisted over time. An increase in bone/joint pain was more pronounced, particularly in the short-term, in patients on exemestane+OFS. Changes of global QoL indicators from baseline were small and similar between treatments over the whole treatment period. Interpretation Overall, from a QoL perspective, there is no strong indication to favor either exemestane+OFS or tamoxifen+OFS. The differential effects of the two treatments on endocrine symptoms burden need to be addressed with patients individually. Funding TEXT and SOFT receive financial support for trial conduct from Pfizer, the International Breast Cancer Study Group and the US National Cancer Institute. Pfizer and Ipsen provide drug supply. See Acknowledgment for grants and grant numbers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring Functioning and Well-Being: The Medical Outcomes Study Approach
Stewart, A., & Ware, J. (1992) · doi:10.7249/cb361 · Cited by 2,689
Exemestane for Breast-Cancer Prevention in Postmenopausal Women
Goss, P. E., Ingle, J. N., Alés-Martínez, J. E., Cheung, A. M., Chlebowski, R. T., Wactawski-Wende, J., McTiernan, A., Robbins, J., Johnson, K. C., Martin, L. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103507 · Cited by 970
Cited by
Burstein, H. J., Curigliano, G., Thürlimann, B., Weber, W. P., Poortmans, P., Regan, M. M., Senn, H. J., Winer, E. P., Gnant, M., Aebi, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.023 · Cited by 821
Self-citationTailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Colleoni, M., Láng, I., Gómez, H. L., Tondini, C., Ciruelos, E., Burstein, H. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803164 · Cited by 684
Self-citationSystemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer
Burstein, H. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1307118 · Cited by 316
Self-citationBurstein, H. J., Lacchetti, C., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. E., Giordano, S. H., Hudis, C. A., Solky, A. J., Stearns, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.9573 · Cited by 300
Self-citationFranzoi, M. A., Agostinetto, E., Perachino, M., Del Mastro, L., de Azambuja, E., Vaz-Luis, I., Partridge, A. H., & Lambertini, M. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30666-5 · Cited by 290
Metadata
- Authors
- Bernhard, J., Luo, W., Ribi, K., Colleoni, M., Burstein, H. J., Tondini, C., Pinotti, G., Spazzapan, S., Ruhstaller, T., Puglisi, F., Pavesi, L., Parmar, V., Regan, M. M., Pagani, O., Fleming, G. F., Francis, P. A., Price, K. N., Coates, A. S., Gelber, R. D., Goldhirsch, A., & Walley, B. A.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2015-07
- Volume
- 16
- Issue
- 7
- Pages
- 848-858
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W1890169097
- Cited by
- 178
- References
- 2
- FWCI
- 7.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. https://app.cochat.ai/papers/10.1016/s1470-2045(15)00049-2
- The paper
- Bernhard, J., Luo, W., Ribi, K., Colleoni, M., Burstein, H. J., Tondini, C., Pinotti, G., Spazzapan, S., Ruhstaller, T., Puglisi, F., Pavesi, L., Parmar, V., Regan, M. M., Pagani, O., Fleming, G. F., Francis, P. A., Price, K. N., Coates, A. S., Gelber, R. D., . . . Walley, B. A. (2015). Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(15)00049-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.